A cancer vaccine with dendritic cells differentiated with GM-CSF and IFN α and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.

Conclusion: We identified squaric acid as a novel immunogenic treatment of tumor cells for cancer vaccines particularly efficient in prolonging animal survival when used in combination with IFNα-differentiated DCs. These promising results support future efforts for the clinical translation of this approach. PMID: 30211081 [PubMed]
Source: BioImpacts - Category: Research Tags: Bioimpacts Source Type: research